Royalty Report: Drugs, Disease, Therapeutic – Collection: 372569

Compound means Retigabine, and will include (i) any compounds with alternative names but with the same chemical structure as Retigabine, and (ii) any salts, esters, solvates and/or crystalline polymorphs of Retigabine as well as any compounds that are transformed into Retigabine following its introduction into the body of a mammal, their stereoisomers, racemates, salts, solvates and/or crystalline polymorphs or any of their active metabolites either prior to or following introduction into the body of a mammal.

Licensor grants an exclusive license to use the Licensor Trademarks in connection with any Licensed Products that Licensee uses, markets, promotes, distributes, imports, commercializes, offers for sale or sells within the Field and Territory either directly on its own and/or through its Affiliates, sublicensee, and/or distributors.

Licensor grants a non-exclusive license to use the Licensor Logo on all packaging materials, promotional materials and documents that are used by Licensee either directly on its own and/or through its sublicensee, contractors or distributors in connection with the development, promotion, marketing, offer for sale, sale, import and commercialization of the Licensed Products.

Licensor grants a worldwide, non-exclusive license, without any right to sub-license, under the Licensor Patents and Licensor Know-How to develop or have developed on its behalf, Licensed Products for use and sale within the Field and the Territory,

Licensed Products means the xxx 2-093 Product and all other products, including any current or future dosages, formulations, improvements and/or delivery modes comprising xxx 2-093 and all possible metabolites, salts, hydrates, polymorphs, crystalline forms, solvates and prodrugs thereof, including any present and future combination products containing xxx 2-093 or a metabolite, salt, hydrate, polymorph, crystalline form, solvate or prodrug thereof, as one of the active ingredients.

xxx 2-093 means Licensors proprietary compound (S)-(-)-10-acetoxy-10,11- dihydro-SH-dibenz/b,f/azepine-5-carboxamide, known under the International Nonproprietary Name (INN) Eslicarbazepine Acetate.

Licensor Trademarks mean ERELIB' and PAZZUL.

The logo is BIAL.

SEP-0002093 is a new chemical entity which is intended to offer patients suffering with partial epilepsy additional control of their seizures and improved quality of life. Licensor has completed a Phase III program in Europe for the adjunctive treatment of epilepsy.

The Field means all human and non-human diagnostic, prophylactic and therapeutic uses of the Licensed Products for adjunctive use in Adult Partial Epileptic Seizures and any and all new indications, including but not limited to Epilepsy Monotherapy, Trigeminal Neuralgia, Diabetic Neuropathic Pain and Post-herpetic Neuralgia.

Licensor grants a worldwide, non-exclusive license to the Licensor Trademark, solely for the purpose of fulfilling Licensees obligations in relation to this Agreement.

Other Compound means diazepam (7-chloro-l-methyl-5-phenyl-l ,3-dihydro-2H-1 ,4- benzodiazepin-2-one). including all salts, esters, complexes, chelates, hydrates, isomers, stereoisomers, crystalline forms, amorphous forms, prodrugs (including all compounds that are metabolized or dissolve into the same active moiety in the body), solvates, metabolites/metabolic precursors, and pegylated form thereof.

Product means the nasal formulation of Product Intermediate incorporated or filled into a Device.

Buccal Formulation means formulations of Product Intermediate for administration by placing in the mouth for absorption through the cheek, the gum or the upper or lower inside lip without swallowing, achieved by means of a muco adhesive, including but not limited to any specific formulation that may be selected for commercialization.

Field means the use as a prescription or over-the-counter pharmaceutical product in humans, specifically excluding diagnostic use.

Licensee acquired global rights to a novel nasal lorazepam formulation for the treatment of emergency seizures in epilepsy patients.

Licensor grants a non-exclusive, worldwide sublicense to make or use any analytical reference standards, intermediate or metabolite of the Compound or Product which may be claimed in Patents limited solely to making or using the Compound or Product.

Licensee represents and warrants that during the term of this Sub license Agreement, neither it, an Affiliate or a Sublicensee shall license, develop, have developed, manufacture, have manufactured, sell or have sold any of the following compounds or products classified as an atypical antipsychotic i.e. Olanzapine, Sertindole, Seroquel, Ziprasadone, Risperidone.

Compound shall mean the chemical compound known as Iloperidone, whose specific chemical name is 1 -[ 4-(3-[ 4-(6-fluoro-l ,2-benzisoxazol-3-y 1)-1-piperidinyl]propoxy ]-3-methoxyphcnyl]ethanone, including any salts, hydrates, solvates, and/or stereoisomers thereof, and only the metabolites listed hereto, including any salts, hydrates, solvates and/or stereoisomers of such metabolites.

Diacylglycerol O-acyltransferase 1 is an enzyme that in humans is encoded by the DGAT1 gene.

Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.

“TR-Beta Compounds” means Metabasis’ MB07811 and MB10866 compounds, and any other compounds comprised by the TR-Beta Patents, and any salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers, polymorphs, and derivatives of such compounds.